Prevention of Rh-haemolytic disease: final results of the "high-risk" clinical trial. A combined study from centres in England and Baltimore.
The final results are reported of a trial of about 1,000 mug of anti-D gammaglobulin given intramuscularly to a selected high-risk group of Rh-negative primiparae just delivered of an ABO-compatible Rh-positive baby, the aim being to prevent them becoming immunized to Rh. Six months after delivery only 1 out of 173 treated mothers had been immunized as against 38 out of 176 controls. The crucial test of the prophylactic therapy depends on the presence or otherwise of anti-D at the end of a second Rh-positive pregnancy. Of 86 treated mothers two had antibodies at this time compared with 20 out of 65 controls.The results show a high degree of protection in this group of mothers.
D000017:ABO Blood-Group System; D000917:Antibody Formation; D002986:Clinical Trials as Topic; D004739:England; D004899:Erythroblastosis, Fetal / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007110:Immunity, Active; D007112:Immunity, Maternally-Acquired; D007273:Injections, Intramuscular; D007518:Isoantibodies; D008396:Maryland; D010298:Parity; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System; D005719:gamma-Globulins / Q000627:therapeutic use*
D000017:ABO Blood-Group System; D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System; D005719:gamma-Globulins